Biotech Blueprint

Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100

The FDA loses its commissioner amid mounting instability, BMS makes the biggest pharma-China deal of 2026, and a clean gene therapy dataset gives…

13 hrs ago • Katerina Roznik

4

FDA Approves the First PROTAC in History, a $1B siRNA Wave Hits Cardiometabolic Disease, and Cytokinetics Cracks Non-Obstructive HCM – This…

Targeted protein degradation gets its first regulatory template, Madrigal and GSK bet on genetically defined MASH and obesity, and aficamten wins where…

May 8 • Katerina Roznik

14

1

1

The First In Vivo CRISPR Therapy to Win a Phase 3 Trial, and the $1.9B Acquisition Made Two Days Later – This Week in Biotech #98

Intellia's hereditary angioedema result validates in vivo gene editing, Sun Pharma makes the biggest biopharma deal of 2026, and the FDA draws a new…

May 1 • Katerina Roznik

12

1

April 2026

The Largest Biotech IPO on Record and a New HIV Treatment Option – This Week in Biotech #97

Merck's Idvynso offers the first integrase-free HIV switch option, Replimune cuts 60% of staff after a second FDA rejection, and Kailera's $625M debut…

Apr 24 • Katerina Roznik

9

1

Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96

The most compelling pancreatic cancer trial result in a decade, Lilly's oral GLP-1 eyes a diabetes label, and the FDA is reconsidering compounding…

Apr 17 • Katerina Roznik

10

1

Gilead Goes All-In on ADCs, Merck's Hidden $1B Discount, and Lilly Launches Its Oral GLP-1 – This Week in Biotech #95

The oral GLP-1 race officially starts at $149/month, and updated leukemia data quietly reshaped a blockbuster acquisition (April 3-9, 2026).

Apr 10 • Katerina Roznik

10

100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94

Orforglipron becomes the first oral weight loss pill approved without food or water timing restrictions, Biogen buys Apellis, and trade policy just…

Apr 3 • Katerina Roznik

15

2

March 2026

Merck's $6.7B Bet and the First Drug to Reach the Brain in Hunter Syndrome – This Week in Biotech #93

Plus Sarepta's first human proof for gene-silencing in muscular dystrophy, a CDC leadership vacuum, and what it all means for biotech (March 20-26…

Mar 27 • Katerina Roznik

13

2

TrumpRx Price Claims Get Fact-Checked, RFK Jr.’s Vaccine Overhaul Paused, Lilly’s Retatrutide Hits Phase 3 – This Week in Biotech #92

A judge freezes ACIP changes, J&J wins a plaque psoriasis pill approval, and Lilly raises the bar again in obesity and diabetes (Mar 13-19, 2026).

Mar 20 • Katerina Roznik

8

1

This Week in Biotech: Brief Update

On pause for two weeks, back March 20.

Mar 6 • Katerina Roznik

9

2

February 2026

Novo's CagriSema Loses to Zepbound, Grail Stumbles, FDA Hardens Its Stance – This Week in Biotech #91

CagriSema lost the obesity head-to-head with Lilly's Zepbound, Galleri misses its primary endpoint, and the FDA signals tougher tolerance for invasive…

Feb 27 • Katerina Roznik

4

FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90

Plus Compass psilocybin Phase 3 win and China’s biotech licensing surge (Feb 13-19, 2026).

Feb 20 • Katerina Roznik

7

1